AbbVie’s SKYRIZI wins FDA approval for ulcerative colitis treatment
The U.S. Food and Drug Administration (FDA) has approved SKYRIZI (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor developed by AbbVie, for the treatment of adults with moderately to severely active ulcerative colitis. This marks a significant milestone as SKYRIZI becomes the first IL-23 specific inhibitor approved for this condition, in addition to its approval for moderate to […]